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The C-terminal domain (CTD) in linker histones
antagonizes anti-apoptotic proteins to modulate
apoptotic outcomes at the mitochondrion
M Garg1,2, N Ramdas1, M Vijayalakshmi1,4, GV Shivashankar1,3 and A Sarin*,1
The loss of mitochondrial integrity as a consequence of apoptogenic complexes formed on the outer membrane constitutes a
key step in controlling progression of apoptotic cascades. Here, we show that multiple members of the linker histone (LH) family
of proteins modify apoptotic cascades initiated by the Bcl-2 protein Bak, and impart resistance to its endogenous antagonist
Bcl-xL. Our experiments reveal apoptogenic capabilities equivalent to those documented for H1.2 in H1.1 and H1.3 isoforms.
Deletion mutants of H1.2 and site-directed mutagenesis of H1.1 and H1.2 implicated the C-terminal domain in apoptogenic
activity. In this context, disruption of protein kinase-C activity using chemical inhibitors, dominant-negative approaches and
RNA interference coupled with site-directed modifications in H1.1, identified the protein kinase-Cb1 isoform as a repressor of
H1.1/H1.3 apoptogenic activity. Finally, a H1.2 C-terminal tail recombinant attenuated Bcl-xl inhibition of Bak-induced apoptosis,
suggesting that the C-terminal domain was necessary and sufficient for apoptogenic functions. Thus, integration with apoptotic
intermediates (via C-terminal tail interactions) may constitute a more generalized function of LH isoforms in apoptotic cascades.
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Bcl-2 family proteins determine mitochondrial involvement in
death cascades that eliminate damaged and defective
cells .1,2 In mammalian cells, apoptosis may be coordinated
by transmembrane proteins of the Tumor Necrosis Receptor
superfamily,3 which respond to extracellular signals to
activate preformed adapter proteins and cytotoxic inter-
mediates. Apoptosis is also initiated by internal stressors
that in response to varied cues recruit adapter proteins,
predominantly of the Bcl-2 family, to precipitate the release
of apoptogenic intermediates from the mitochondrion.1,2
Damage to the genome triggers the latter pathway,4,5
suggesting possible mechanisms that relay apoptotic signals
to the mitochondrion. Apart from the well-studied protein
p53, which has been extensively investigated in this
context,6,7 molecular intermediates such as Nur77,
caspase-2 and more recently the linker histone (LH) H1.2
have been demonstrated to transmit apoptogenic signals
from the nucleus to the mitochondrion in response to
genotoxic damage.8,9
The LHs, which comprise eight subtypes, consist of a highly
conserved globular domain and less conserved N-and
C-terminal domains. The C-terminal domain (CTD) of the LH
generally includes B40% lysine residues, 20–35% alanine
residues and 15% proline residues.10 Two distinct functional
regions of 24 amino acids each that facilitate DNA binding and
chromatin condensation have also been described.11 Specific
regions in the CTD have been shown to facilitate protein–
protein interactions with binding affinities of LHs thought to be
determined by the length of the C-terminal tail.10,12,13
Consistent with this, measures of LH dynamics by fluores-
cence recovery after photobleaching (FRAP) analysis have
shown that isotypes H1.3, H1.4 and H1.5 with longer CTDs
exchange slowly (t1/2B15 min), when compared with LH with
shorter CTDs (H1.0, H1.1 and H1.2) and faster t1/2 of
1–2 min.12 Indeed, the dynamics of LH is a key feature thought
to underlie varied outcomes characterized by LH involve-
ment.14–17 In this context, the molecular logic underlying the
singular involvement of LH isoform H1.2 in apoptotic
cascades or interactions at the mitochondrial outer membrane
is not known.
In this study, using recombinant approaches we characterize
components of multi-protein apoptogenic complexes that
characterize LH functions at the mitochondrion. We also
investigate intrinsic properties of LHs controlling apoptogenic
function using functional and biophysical assays. Validating
predictions from these experiments, we demonstrate that
proapoptotic functions of LH isoforms (H1.1, H1.2 and
possibly H1.3) reside in the CTD and are demonstrable in
the context of apoptosis triggered by the proapoptotic Bak and
its regulation by Bcl-xL.
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Results
H1.2 modulates anti-apoptotic activity. The Bcl-2 family
protein Bcl-xL is a well-characterized antagonist of Bak-
induced apoptosis; however, its anti-apoptotic activity was
attenuated in cells coexpressing recombinant linker histone
H1.2 and Bak (Figure 1a). Notably, recombinant H1.2 did not
trigger apoptosis when expressed alone, nor did it increase
Bak-induced apoptotic damage (Figure 1a). Analyses by
confocal microscopy indicated that H1.2 (tagged with EGFP)
did not modify the spatial patterns of Bak (RFP-tagged)
distribution in cells (Figure 1b). However, Bcl-xL successfully
inhibited apoptosis when Bak was coexpressed with the H1.1
isoform (Figure 1c). Although Bax and Bak have several
overlapping structural and functional features, H1.2 did not
modulate Bcl-xL regulation of Bax activity (Figure 1d).
Consistently, Bak-H1.2 induced apoptosis, in the presence
or absence of Bcl-xL, in cells treated with siRNA to
Bax (Supplementary Figures 1A and B). The apoptogenic
capabilities of H1.2 were not restricted to Bcl-xL as
hexokinase-II-mediated inhibition of Bak activity was
also attenuated in cells coexpressing H1.2 (Figure 1e).
Inhibition of nuclear export machinery, using leptomycin B
(LMB) blocked the effect of H1.2, implicating signaling
from the nucleus in this cascade (Figure 1f). To understand
the mechanism underlying H1.2 activity, molecular
intermediates of the apoptotic pathway triggered in cells
expressing Bak and H1.2 were characterized in the experi-
ments that follow.
H1.2 reprograms Bak-mediated apoptotic outputs. In
most instances, Bak is thought to compromise mitochondrial
outer membrane integrity to release cytochrome c from
the inter-membrane space (MIMS), which catalyzes the
activation of a caspase-9-dependent apoptotic cascade.18
However, Bak and H1.2 (Bak-H1.2)-activated apoptosis was
not inhibited by coexpressing a dominant-negative form of
caspase-9 (Figure 2a), suggesting that cytochrome c was not
a key intermediate in Bak-H1.2-induced death. Apoptosis-
inducing factor (AIF) is another resident of the MIMS that is
released following the loss of mitochondrial outer membrane
integrity and translocates to the nucleus and causes DNA
fragmentation.19 Knockdown of AIF using RNA interference
blocked Bak-H1.2-mediated apoptosis, positioning the mole-
cule as a key intermediate in this signaling pathway
(Figure 2b). Notably, AIF ablation was without effect on
apoptosis induced by Bak or Bak-H1.1 (Figure 2b), although
apoptotic damage is not different in the three groups. In this
context, AIF translocation to the nucleus was detected in cell
populations transfected with Bak-H1.2, whereas in cells
transfected with Bak-H1.1, AIF was detected in the non-
nuclear fraction (Figure 2c), which is consistent with its
regulation of Bak-H1.2-dependent apoptosis. Phosphorylation
of histone H2AX-Ser139 (g-H2AX) is a hallmark of DNA
damage20 and a molecular signature of AIF activity.21
Supporting the involvement of AIF in Bak-H1.2-induced
apoptosis, gH2A.X reactivity was detected in cell lysates
generated from Bak-H1.2 transfected cells and not in the Bak
transfected group, although H2A.X was comparable in both
Figure 1 H1.2 modulates Bak-mediated apoptosis (a) Apoptotic nuclear damage in cells co-transfected with EGFP or Bak-RFP or Bak-RFPþH1.2-EGFP with or without
Bcl-xL and (b) Confocal images of transfected cells (representative of minimum 60 cells). Scale bar, 5mm; *Po0.001 (c and d) Apoptotic nuclear damage induced by
Bak-RFP±H1.1-EGFP (c) or with Bax-EGFP±H1.2-RFP (d) transfected with or without Bcl-xL. (e and f) Apoptotic nuclear damage in cells transfected with (e) Bak-RFP or
Bak-RFPþH1.2-EGFP with or without HKII (hexokinase-II); or (f) Bak-EGFPþH1.2-RFP±Bcl-xL treated with LMB (0.3 ng/ml) or vehicle control added 6 h
post-transfection. In a, c and d–f, apoptotic damage was assessed 18 h post-transfection. Data plotted are mean±S.D. from three independent experiments
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groups (Figure 2d). Immunostaining for gH2A.X yielded
positive staining in cells transfected with Bak-H1.2, whereas
the modified form was not detected in cells co-transfected with
Bak and GFP (Figures 2e and f and Supplementary Figures
2A and B). Again the extent of apoptotic nuclear damage is not
different in these groups. Collectively, these experiments
demonstrate that H1.2 has distinct consequences for Bak
regulation and activity, albeit apoptotic signaling is coordinated
by mitochondrial intermediates.
Molecular complexes formed on the mitochondrial outer
membrane regulate the release of intermediates sequestered
in the organelle, which propagate apoptotic cascades. Bak is
a mitochondrial resident and its activity is controlled by ligands
such as BH3 domain-only proteins22,23 and molecules
controlling mitochondrial remodeling.24,25 Therefore, we
assessed whether complexes formed by Bak and Bak-H1.2
differed in molecular constitution. Ablation (using siRNA) of
the BH3 domain only proteins BIM or BID was without effect
on Bak-H1.2 signaling (Supplementary Figures 2C–F).
However, the adapter protein PUMA (p53-upregulated mod-
ulator of apoptosis) was critical for apoptotic signaling, as its
ablation attenuated H1.2 activity and restored Bcl-xL function
(Figures 2g and h). Similar approaches demonstrated a
requirement for a protein regulating mitochondrial fusion,
mitofusin-1 (Mfn-1) but not the Mfn-2 isoform or the dynamin-
related protein (Drp)-1, which controls organelle fission,
in the Bak-H1.2 apoptotic cascade (Figures 2i and j and
Supplementary Figures 2G–J). These experiments indicate a
distinct configuration of molecules forming apoptogenic
complexes associated with Bak-H1.2 activity, perhaps deter-
mining the release of intermediates from the mitochondria.
Subsequent experiments attempted to identify specific
domains in H1.2 that control its activity in the mitochondrion.
Molecular characterization of linker histone activity in
the apoptotic response. LH isoforms are distinguished by
the sequences of their N- and C-terminal tails12,14 and we
focused on the tail domains to examine intrinsic determinants
of apoptogenic activity. As shown for H1.1, coexpressing H1.3
or H1.5 with Bak did not confer resistance to Bcl-xL (Figures
3a and b). More careful examination of the C-terminal tails
revealed that the motif KVVKP, which appears only once in
H1.2, differed from the motif (present multiple times) in H1.1
and H1.3 by a threonine residue (KTAKP) (Figure 3c and
Supplementary Figure 3A). To test whether this was critical for
the functional differences observed, site-directed substitution
of Valine-202 to Threonine was employed to generate the
H1.2 variant H1.2V202T-EGFP.
Figure 2 AIF regulates Bak-H1.2-mediated apoptosis (a and b) Apoptotic nuclear damage in cells (a) transfected with Bak-EGFP or Bak-EGFPþH1.2-RFP with or
without DNC9 (b) pretreated with siRNA to AIF or the scrambled control for 48 h and then transfected with Bak-EGFP or Bak-EGFPþH1.1-RFP or Bak-EGFPþH1.2-RFP.
Inset: Representative immunoblot for AIF protein and a-tubulin in cells treated with siRNA to AIF. (c) Immunoblots derived from subcellular fractionation of experimental groups
transfected with indicated plasmids and cultured for 12 h. The fractions were probed for AIF, HP1a and Cox-IV. (d) Cells transfected with Bak-RFP or Bak-RFPþH1.2-EGFP
were cultured for 12 h and cell lysates analyzed for gH2A.X and unmodified H2A.X protein by western blot analysis. Tubulin established parity of loading. (e and f)
Quantification of gH2A.X-positive cells (e) in groups transfected with Bak-RFPþGFP or Bak-RFPþH1.2-EGFP. Representative confocal images of immunostaining for
gH2A.X (f), from the analysis ofB75 cells for each condition from two experiments is shown. (g–j) Apoptotic damage in cells pretreated for 48 h with siRNA to PUMA or the
scrambled control (g) or Mfn1 (j) and transfected with indicated combination of recombinants. Immunoblots for PUMA (h) and Mfn1 (i) protein in cells treated with respective
siRNA. a-tubulin was used as the loading control. In a, b, g and j, apoptotic nuclear damage was scored 18 h post-transfection. Data plotted are mean±S.D. from three
independent experiments. *Po0.001 **Po0.01
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H1.2V202T localized to the nucleus, as assessed by
confocal microscopy (Figure 3d). Apoptosis induced by
coexpressing Bak and the H1.2V202T recombinant was
inhibited by Bcl-xL and DNCasp-9 (Figures 3e and f) and
g-H2A.X reactivity was not elicited in Bak-H1.2V202T expres-
sing cells (Figure 3g) strongly suggesting that the KVVKP
sequence controlled functions in H1.2. This prompted a
reciprocal change in the H1.1 isoform, to generate the
H1.1T204V recombinant. Apoptosis triggered by coexpres-
sing H1.1T204V with Bak, was not attenuated by the ablation
of endogenous H1.2 and was resistant to regulation by Bcl-xL
(Figure 3h), thereby mimicking apoptogenic functions of H1.2.
The modified H1.1 recombinant was also localized to the
nucleus (Figure 3i). Further, LMB restored Bcl-xL regulation
of Bak-H1.1T204V-mediated apoptosis (Supplementary
Figure 3B). Despite the differences in assays of apoptosis,
the dynamics of the linker histone mutants are consistent with
earlier studies13 and the modified recombinants were compar-
able to the parent proteins (in the presence or absence of
Bak-Bcl-xL), (Figures 3j and k and Supplementary Figures
3C–E) suggesting that chromatin compaction functions of the
LHs were not changed. We then considered that the threonine
residue in the H1.1 C-terminal tail was a site for post-
translational modification, which controlled its nonnuclear
(apoptogenic) activity. This possibility was supported by the
observation that upon substitution with a negatively charged
amino acid, the resultant H1.2V202D recombinant (possibly
functioning as a phospho-mimetic) did not attenuate Bcl-xL
activity (Figure 3l).
LH functions are regulated by protein kinase-C (PKC)
activity. Further examination of the C-terminal tail
sequences suggested that the motif (KTAKP) might be a
putative PKC-a/b target site (Supplementary Figure 3A).
We first tested the outcome of modifying PKC activity (on H1.1
and H1.3 in apoptosis assays), using pharmacological
approaches. In the presence of Go¨6976 or BIM-1, inhibitors
of PKC enzymes, coexpression of H1.1 or H1.3 attenuated
Bcl-xL activity (Figures 4a and b and Supplementary
Figure 4A), whereas coexpression of H1.5 did not modulate
Bcl-xL activity (Figure 4b and Supplementary Figure 4A). We
show the loss of phospho-PKC activity, assessed by
immunoblot analysis of lysates prepared from cells treated
with the PKC inhibitors (Figure 4c and Supplementary
Figure 4B). As PKC can regulate core histone functions,26,27
we extended the analysis to the induced phosphorylation by
PKC of core histone H3-GFP and ascertained, as reported by
others,26 that this is sensitive to inhibition by BIM-1
(Supplementary Figures 4C and D). Next, we asked whether
modulation of PKC activity impinged on nuclear dynamics of
the LH proteins. As before, FRAP measures for this analysis
revealed no differences in LH dynamics following treatment
Figure 3 Characterization of H1.2 domains modulating Bak-mediated apoptosis (a and b) Apoptotic nuclear damage in cells transfected with Bak-EGFP and Bak-
EGFPþH1.3-RFP (a) or Bak-EGFPþH1.5-RFP (b) with or without Bcl-xL. *Po0.001 (c) Schematic representation of a part of amino acid sequence of the CTD of H1.1 and
H1.2. The asterisk (*) indicates the amino acid residue mutated within the boxed motif. The numbers indicate total amino acid residues in each isoform. (d) Representative
confocal images showing nuclear localization of EGFP-tagged H1.2 or H1.2V202T recombinant in HeLa cells (representative of minimum 100 cells). Scale bar, 5mm (e and f)
Apoptotic damage in cells expressing Bak-RFP co-transfected with H1.2 recombinants with or without Bcl-xL (e) or DNC9 (f). (g) Confocal images of cells expressing the
different H1.2 recombinants with Bak-RFPþBcl-xL and 12 h post-transfection, immunostained with an antibody to gH2A.X (Ser 139). Scale bar, 5 mm (h) Apoptotic damage in
cells pretreated with siRNA to H1.2 or the scrambled control for 48 h and then transfected with BakþH1.1 or BakþH1.1T204V with or without Bcl-xL. Inset: Immunoblot for
H1.2 and a-tubulin protein in cells treated with siRNA to H1.2. (i) Representative confocal images showing nuclear localization of EGFP-tagged H1.1 recombinants
(representative of minimum 50 cells). Scale bar, 5 mm (j and k) FRAP analysis in the nucleus of cells expressing H1.1-EGFP or H1.2-EGFP recombinants with or without
BakþBcl-xL, 12 h post-transfection. Percentage recovery is plotted for a period of 100 s. Data are presented as mean±S.E.M. (l) Apoptosis induced by Bak-RFP or Bak-
RFPþH1.2V202D-EGFP with or without Bcl-xL. Inset: Representative confocal image showing nuclear localization of EGFP-tagged H1.2V202D recombinant (representative
of 75 cells). Scale bar, 5mm Apoptotic nuclear damage was assessed 18 h post-transfection. In a, b, e, h and i, data plotted are mean±S.D. from three independent
experiments and in f, from four independent experiments
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with the PKC inhibitors, suggesting that PKC activity may not
modulate LH mobility in the nucleus (Figure 4d and
Supplementary Figures 4E and F). Further, cell fractionations
followed by immunoblot analysis indicated that unmodified
H1.1 protein was detected in the cytoplasm, as was
the H1.1T204V recombinant (Figures 4e and f and
Supplementary Figures 4G and H). It may be noted,
however, that these observations may arise from the
enhanced mobility of LHs when compared with the less-
mobile HP1a protein used to mark the nuclear fraction.
However, the PKC modification, while not affecting activities
in the nucleus, may stabilize LH function in the cytoplasm,
although the underlying mechanism(s) remains to be
ascertained.
Dominant-negative and RNAi approaches were used to
identify isoform(s) of the PKC family that regulated this
activity. Ablation of the PKCa or PKC-b isoforms using RNAi
indicated a requirement for the latter in the regulation of H1.1
apoptogenic activity (Figures 5a and b). The regulation was
lost with H1.1T204V and restored when H1.2V202T was
included in functional assays (Figures 5c and d). Dominant-
negative approaches revealed that the PKC-b1 and not the
PKC-b2 isoform regulated this activity (Figures 5e and f). To
more directly test the involvement of the CTD suggested by
the aforementioned experiments, we undertook a deletion-
mutation analysis of H1.2.
The H1.2 CTD is required for apoptogenic activity. A tail-
less H1.2 recombinant (H1.2TL) did not regulate Bcl-xL
function vis-a-vis Bak-induced apoptosis (Figure 6a), positing
the tail regions as key molecular regulators of H1.2 function.
Further, an N-terminal-deleted form of H1.2 (H1.2DNTD)
retained apoptogenic activity, attenuating Bcl-xL regulation
of Bak-induced apoptosis as efficiently as the full-length H1.2
(Figure 6b) implicating the CTD in apoptotic function.
In addition, the dynamics of H1.2DNTD as measured by FRAP
analysis was only moderately different from parent H1.228
(Supplementary Figures 5A and B). As a consequence of all
the analyses thus far, we tested whether a C-terminal tail
recombinant of H1.2 recapitulated apoptogenic capabilities of
full-length H1.2. In initial experiments, ectopic expression of
the H1.2 C-terminal tail-EGFP (H1.2CTD), when coexpressed
with Bak and Bcl-xL was without effect in that there was no
attenuation of Bcl-xL function (Figure 6c). Whereas this
experiment indicates that H1.2 CTD does not have apopto-
genic activity, western blot analysis for the GFP-tagged CTD
recombinant in cells suggested that the CTD was being
degraded, as it was only weakly detected in cell lysates
(Figure 6d). However, in lysates generated from cells
cultured in the presence of MG-132—a cell-permeable,
broad-spectrum, protease inhibitor—the CTD recombinant
was readily detected in immunoblots (Figure 6d). This
suggested that the lack of apoptogenic activity of the CTD
in functional assays might be attributed to its degradation. In
support of this, in cultures treated with MG132, H1.2CTD
attenuated Bcl-xL activity (Figure 6e). We could rule out the
possibility that this was an artifact induced by MG132 as the
inhibitor did not modulate outcomes in cells that were not
Figure 4 Regulation of LH function by PKC (a and b) Apoptotic nuclear damage in cells transfected with (a) BakþH1.1 or BakþH1.1-T204V or (b) BakþH1.3 or
BakþH1.5 with Bcl-xL, with Go¨6976 (500 nM) or vehicle control added 6 h post-transfection for a total culture duration of 18 h. Data plotted are mean±S.D. from three
independent experiments. (c) Representative immunoblot for phospho(Ser)-PKC substrate protein and a-tubulin in cells treated with Go¨6976 (500 nM) or vehicle control for
12 h. The spacer indicates one lane removed during processing of the image for presentation. (d) FRAP analysis in the nucleus of cells expressing H1.1-EGFP or H1.2-EGFP
recombinants, with 500 nM BIM1 or Go¨6976 added 6 h post-transfection. Percentage recovery is plotted for a period of 100 s (n¼ 15 for H1.1-EGFP, n¼ 12 for H1.1þ BIM1,
n¼ 13 for H1.1þGo¨6976, n¼ 10 for H1.2-EGFP, n¼ 8 for H1.2þBIM1 and n¼ 9 for H1.2þGo¨6976). Data plotted are mean±S.E.M. (e and f) Immunoblots of nuclear
and cytoplasmic fractions of HEK cells transfected with indicated recombinants for 12 h and probed for GFP and a-tubulin (e) and with HP1a (f) purity control
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co-transfected with H1.2CTD (Figures 6e and f). Taken
together, the data suggest that by preventing the degradation
of the H1.2CTD, MG132 revealed the former’s apoptogenic
function and the consequent propagation of Bak-induced
apoptosis in cells coexpressing Bcl-xL. Thus, the effect of the
CTD commensurates with the apoptogenic activity observed
with LH1.2.
Discussion
The LH H1.2 is a relatively recent addition to the group of
nuclear resident proteins implicated in apoptotic cascades
coordinated by the mitochondrion.8,9 Earlier work has
demonstrated roles for H1.2 in triggering apoptosis in different
cell types and in response to diverse stimuli. However,
intrinsic molecular features underlying this function or
mechanisms regulating the specific involvement of the H1.2
isoform are not known and are primarily investigated in this
study.
The CTD of individual LH isoforms is the primary
determinant of their chromatin-binding affinity, which regu-
lates chromatin condensation, gene expression and other
functions.15,16,28,29 The CTD is an intrinsically disordered
domain, that is, unstructured in solution, but acquires
secondary structure upon interaction with DNA,11 indicating
that the composition and distribution of positively charged
amino acids determines its structure and hence the differential
affinity or chromatin condensing property of various isoforms.
It has been proposed that regions of intrinsic disorder in tail
domains drive the wide-ranging molecular interactions
mediated by LHs, several of which, may be determined by
the CTD.11,15 These are posited to result in well-defined
conformations as a consequence of interactions with a target
molecule.16,17 Collectively, the dynamics of LHs are impli-
cated in a number of functional contexts such as differentia-
tion, genome regulation and integrity and cellular
homeostasis.30–32 In this regard, analysis of histone subtypes
isolated from rat brain tissue identified high-affinity isoforms
(H1.3, H1.4), intermediate-affinity isoforms (H1.2, H1.5) and
low-affinity isoform (H1.1).33 FRAP analysis of GFP-tagged
subtypes in cell-based assays showed that H1.4 and H1.5 are
most tightly bound to chromatin, whereas H1.0 and H1.3 have
intermediate binding and H1.1 and H1.2 are weakly
bound.12,34 Further, H1.3-1.5 have higher DNA condensing
properties than H1.1 and/or H1.2,35,36 suggesting the
possibility that low-affinity H1 isoforms (H1.1 and H1.2) may
be likely early nuclear intermediates that leak into the
cytoplasm to initiate apoptotic signaling. However, more
Figure 5 Apoptogenic activity in LH H1.1 is regulated by PKCb2 (a–c) Apoptotic damage in cells pretreated with siRNA to PKCa or PKCb or a scrambled control for 48 h
were transfected with (a) Bak-RFPþH1.1-EGFP±Bcl-xL or (c) Bak-RFPþH1.1T204V-EGFP±Bcl-xL. (b) Immunoblots for PKCa and PKCb2 in cells treated with respective
siRNA. a-tubulin was used as the loading control. (d–f) Apoptotic damage in cells (d) pretreated with siRNA to PKCa or PKCb or the scrambled control for 48 h were
transfected with Bak-RFPþH1.2V202T-EGFP±Bcl-xL; (e) transfected with Bak-RFPþH1.1-EGFP±Bcl-xL with or without DN-PKCa; (f) transfected with Bak-RFPþH1.1-
EGFP±Bcl-xL with or without DN-PKCb1 or DN-PKCb2. *Po0.001 In a, c and d–f, apoptotic damage was assessed 18 h post-transfection. Data are plotted as mean±S.D.
from three independent experiments
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sensitive measures using biophysical and imaging
approaches need to be undertaken to compare the dynamics
and distributions of the different recombinants in conditions
that result in distinct functional outcomes.
The data do support a necessary role for the LH CTD for
apoptogenic functions and present evidence that capabilities
commensurate to those presented by H1.2 are demonstrable
in the LH isoforms H1.1 and H1.3. As H1.1 and H1.2 isoforms
are detected in the cytoplasm in response to apoptotic stimuli,
but only H1.2 is active in our experiments, it suggested that
these isoforms are susceptible to differential regulation in the
cytoplasm. Deletion-mutant and site-directed mutagenesis
analysis implicated specific residues in the CTD, with
apoptogenic function recapitulated by a recombinant CTD
(H1.2CTD). Although the intracellular interactions of the
recombinant remain to be characterized more completely,
it is tempting to speculate that the CTD is not only necessary
but also sufficient for apoptogenic activity mediated by LH1.2.
In the experimental framework employed, LHs did not
antagonize the closely related anti-apoptotic protein Bcl-2
although the generality of these two observations remain to be
established. Thus, we primarily investigated interactions that
impinge on interactions of Bcl-xL and the proapoptotic
protein Bak.
In contrast to the H1.2 isoform, apoptogenic capabilities in
the isoforms H1.1 and H1.3 are repressed by the kinase PKC
with gene ablation and dominant-negative approaches
identifying a role for the PKC-b1 isoform in this function.
Although the site(s) where these interactions occur remain to
be ascertained, the data provide a molecular explanation for
the (exclusive) role of the H1.2 isoform in the apoptotic
cascades observed in earlier reports. Although the conse-
quences of PKC phosphorylation on functions in the mito-
chondrion remain to be addressed, the analysis of LH
dynamics argues against the possibility that phosphorylation
by PKC influences the spatial distribution of LHs. However,
phosphorylation may promote interactions or target LHs to
specific compartments or organelles facilitating apoptotic
function, which remains to be investigated further. LHs
modulate outcomes based on binding to chromatin, regulated
in turn, by modifications of chromatin or LHs themselves.37–39
In this context, phosphorylation of tail domains of H1 by the
cdc2 kinase promotes chromatin decondensation hence
increasing accessibility to chromatin modifying enzymes.40,41
Figure 6 The H1.2 CTD is required for apoptogenic activity (a–c) Apoptotic nuclear damage in cells transfected with Bak±H1.2TL (a) or Bak±H1.2DNTD (b) or
Bak-RFPþH1.2CTD-EGFP (c) with or without Bcl-xL. (d) Western blot analysis of lysates generated from cells transfected with H1.2CTD-EGFP were cultured with and without
MG132 (10mM) or the vehicle control for 10 h. Immunoblots were probed with antibodies to GFP or p38MAPK (loading control). (e and f) Apoptotic nuclear damage in cells
expressing the indicated recombinants and MG132 (10 mM) or vehicle control added 6 h post-transfection.In a–c, e and f, apoptotic nuclear damage was assessed 18 h
post-transfection. Data plotted are mean±S.D. *Po0.001; **Po0.01
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FRAP analysis has demonstrated that global changes in
acetylation induced by TSA leads to hyper-acetylation of core
histone tails but not of H1 and by modifying the binding of H1
to chromatin, increases H1 mobility owing to acetylation-
induced alterations in chromatin structure.13
Following DNA breaks, early in the apoptotic process, the
CTD of histone isoforms presents with a decrease in
phosphorylation, which renders linker DNA susceptible to
cleavage by apoptotic nuclease CAD/DFF40.42 Truncation
mutants of recombinant H1.0 have shown that CTD region
proximal to globular domain (97–169) is responsible for
stabilization of condensed chromatin, whereas, CTD
sequences more distal to globular domain (142–193) are
more accessible to other proteins such as DFF40.42–44 These
studies support the observations that phosphorylation of
H1.1T204 by PKC suppresses its proapoptotic activity. We
speculate that H1.1 and H1.3 will be apoptogenic in contexts
where PKC signaling is inhibited or PKC itself is (possibly)
cleaved as reported in cisplatin-induced DNA damage,
characterized by the proteolytic cleavage of PKCd.45
Our experiments show that LH function in the mitochondrion
depended on several proteins apart from Bak and Bcl-xL,
including Mfn-1, a regulator of mitochondrial fusion; as well
as the BH3 domain only protein PUMA, a well-characterized
antagonist of the Bcl-2 family. It is likely that these are initiated
by interactions mediated by the LH-CTD at the MOM and may
determine the release of intermediates from the mitochon-
drion. We confirm the observation made by others that H1.2
selectively modulates Bak and not the closely related homolog
Bax.9 Despite many similarities, the two proteins differ in their
subcellular localization and are activated by BH3 ligands that
bind distinct sites on these two proteins.46 Although the
mechanism of LH regulation of Bak activity remains to be
ascertained, LHs may bind Bak directly, thereby liberating it
from a repressor complex or neutralize Bcl-xL function by
promoting the association with PUMA. Core histones and LHs
are reported to destabilize mitochondria in reconstituted
systems.47 We find that apoptotic cascade triggered by H1.2
is independent of cytochrome c, which differs from the
observations made by Konishi et al.9 This difference may
arise from the nature of the apoptotic stimuli (genotoxic drugs
in the published report) or the cellular contexts, despite the
core dependence on Bak in both systems. Further, as
reported for metabolic stress-induced apoptosis, cell death
is not necessarily always regulated by caspase activation.48,49
Although we do not know the mechanism underlying these
differences, we speculate that as reported in other paradigms,
restricted damage to the MOM alone may cause the release of
AIF before cytochrome c50,51 as the latter, if sequestered in
the mitochondrial inter-membrane space by electrostatic
interactions, would require additional signals for its release.52
Importantly, the experiments do not rule out the exit of
cytochrome c, but suggest instead that AIF is a rate-
determining step in the apoptotic cascade. Given that
molecular intermediates in the Bak-H1.2 apoptotic cascade
are distinct, the possibility that LHs acquire apoptotic activity
or recruit or relocate with additional proteins to the MOM
remains to be investigated.
Collectively, the data indicate that the modulation of
apoptotic outcomes may be a more prevalent feature of the
LH family indicative of a generalized function for LHs in
apoptotic transduction cascades. These possibilities warrant
more detailed examination of LH interactions with Bak in
diverse physiological contexts and across evolutionary
scales.53,54
Materials and Methods
Chemicals and reagents. Antibodies were procured from the following
sources: AIF from Chemicon (Billerica, MA, USA); H1.2, PUMA from Abcam
(Cambridge, MA, USA); HP1a from Upstate Biotechnology (Lake Placid, NY,
USA); a-tubulin from Neomarker (Fremont, CA, USA); Bax, Bid (Hu-specific),
gH2A.X, H2A.X, phospho-(Ser) PKC substrate and PKCa from Cell Signaling
Technology (Beverely, MA, USA); GFP from BD Living Colors (BD, Franklin Lakes,
NJ, USA); Bim from BD Pharmingen (BD); Drp1, Mfn1, Mfn2, p38MAPK and PKC
bI2 (C-18) from Santa Cruz (Santa Cruz, CA, USA). The siRNA to BIM was from
Cell Signaling Technology and all other siRNA were from Dharmacon Inc
(Chicago, IL, USA). Lipofectamine was from Invitrogen (Carlsbad, CA, USA);
Bisindoylmaleimide I (BIM1), Go¨6976, LMB and MG-132 from Calbiochem
(San Diego, CA, USA).
Cells, plasmids and transfections. HeLa and HEK 293T cell lines were
maintained in DMEM supplemented with antibiotics and 10% fetal calf serum
(Hyclone, Logan, UT, USA). The EGFP-tagged site-directed mutants (H1.1-
T204V-EGFP, H1.2-V202T-EGFP, H1.2-V202D-EGFP, H1.2TL-EGFP, H1.2DNTD-
EGFP and H1.2CTD-EGFP), were made by PCR amplification following the
Stratagene QuikChange Multi Site-Directed Mutagenesis manual using following
primers: H1.1T204V-EGFP forward, 50-GACGAAGCCAAAGGTTGCCAAACCCAAG-30;
H1.2V202T-EGFP forward, 50-CGCTAAGCCCAAGACTGTCAAGCCTAAG-30; H1.
2V202D-EGFP forward, 50-CGCTAAGCCCAAGGATGTCAAGCCTAAG-30; H1.2TL-
EGFP forward, 50-GAAGATCTATGCCGGTGTCAGAGCTC-30; H1.2DNTD-EGFP
forward, 50-GAAGATCTATGCCGGTGTCAGAGCTC-30; H1.2CTD-EGFP forward,
50-GAAGATCTATGAAAAAGGCGGGCGGAAC-30; H1.1T204V-EGFP reverse, 50-CTT
GGGTTTGGCAACCTTTGGCTTCGTC-30; H1.2V202T-EGFP reverse, 50-CTTAG
GCTTGACAGTCTTGGGCTTAGCG-30; H1.2V202D-EGFP reverse, 50-CTTAGGC
TTGACATCCTTGGGCTTAGCG-30; H1.2TL-EGFP reverse, 50 ’-CTCAAGCTTAAC
CTTGGGCTTGGCTTC-30; H1.2DNTD / H1.2CTD-EGFP reverse, 50-CGGGATCCTT
TCTTCTTGGGCG-30. Recombinant Bak constructs were made by PCR amplifying
Bak ORF (Origene) and ligating into fluorophore-tagged vectors. All constructs
were in the pEGFP-N1 or pEGFP-N3 backbone and the sequences were
verified by automated sequencing (NCBS, Bangalore, India). Dominant-negative
PKC constructs were from Addgene (Cambridge, MA, USA). Dominant-negative
caspase 9 (DNC9) construct was a kind gift from C. Vincenz (University of Michigan
Medical School, Ann Arbor, MI, USA) and the Bcl-xL plasmid from Richard J. Youle
(NIH, Bethesda, MD, USA).
Cells (0.05 106/ml) were plated in 24-well plate 15–18 h before transfection
with recombinants: EGFP, RFP, Bak-EGFP, Bak-RFP (0.8mg); Bcl-xL, DNC9,
H1.2-EGFP or H1.1-EGFP and related recombinants (1.5–2.5mg) and pcDNA3.0
(empty vector control) to equalize the concentration of DNA across transfection
groups. For transfections with siRNA, cells plated as above, were transfected with
100 nM siRNA and used in functional or biochemical assays 48 h later.
Cells were stained for 3 min with the Hoechst 33342 (1mg/ml) at ambient
temperature and nuclear morphology scored in EGFP or RFP positive cells by
fluorescence microscopy.
Immunostaining. Cells fixed with 1–4% paraformaldehyde (15–20min) at
ambient temperature were permeabilized using ice-cold 100% methanol for
10min. Samples were blocked with 5% BSA in 0.3% Triton-X100–PBS and
incubated with 1 : 200 anti-H2A.X or anti-gH2A.X overnight at 4 1C diluted in
blocking buffer. Secondary antibodies (Alexa Fluor-647) were diluted (1 : 500) in
blocking buffer and samples incubated for 1 h at room temperature. Images were
acquired using Zeiss LSM 510 Meta (63X NA 1.4 objective lens; Carl Zeiss,
Oberkochen, Germany). Fluorescence images of cells were recorded with
sequential excitation and emission conditions for EGFP, RFP or Alexa Fluor-647.
Western blot analysis. Cells (0.3–0.5 106) were lysed in a SDS lysis
buffer. Whole-cell lysates were resolved by SDS-PAGE and transferred to
nitrocellulose membrane (GE Healthcare, Bangalore, India) and incubated
overnight at 4 1C with primary antibodies at concentrations recommended by
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the manufacturers. Membrane was washed three times with TBS–Tween20
followed by HRP-conjugated secondary antibody (CST, 1 : 1000 dilution) for 1 h at
room temperature. Membranes were developed by exposure to X-ray film using
either an Amersham Hyperprocessor (Princeton, NJ, USA) or an ImageQuant LAS
4000 Biomolecular Imager (GE Healthcare). Films were scanned and intensity of
bands were quantified with ImageJ software (NIH, Bethesda, MD, USA).
Subcellular fractionation. Cells (2.5 106) were used as input for
subcellular fractionation. Cytoplasmic and nuclear fractions were obtained
following instructions provided with the NE-PER Nuclear and Cytoplasmic
extraction kit (Thermo Scientific, Waltham, MA, USA). Equivalent volumes of
nuclear and cytoplasmic fractions were boiled in SDS lysis buffer for western blot
analysis.
FRAP analysis. Cells (0.3 106) were plated 15–18 h before transfection
with recombinants: H1.2-EGFP or H1.1-EGFP or related recombinants (0.1mg)
and Bak-RFP (0.7mg). Fluorescence recovery after photo-bleaching (FRAP)
analysis was performed 14–16 h post transfection according to a previously
published protocol34 using a Zeiss LSM 510 Meta NLO, Plan-Apochromat 63X NA
1.4 oil objective. The dynamics of fluorescence recovery of B1.5mm photo-
bleached region was calculated using custom-written MATLAB routines. All FRAP
curves were normalized to prebleach values after background subtraction and
photo-bleaching correction.
Statistical methods. All graphs show data presented as mean±S.D.
derived minimally from three–four independent experiments unless stated
otherwise. FRAP analysis is presented as mean±S.E.M. Statistical significance
was calculated using the two-population Student’s t-test, with the following
confidence intervals: *99.9% and **99%.
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